Abeona Therapeutics Inc. (ABEO)
NCM – Real vaqt narxi. Valyuta: USD
5.61
+0.05 (0.90%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
5.60
-0.01 (-0.15%)
Bozordan keyin: Jun 26, 2026, 6:02 PM EDT
Find any stock by ticker or company name

NCM – Real vaqt narxi. Valyuta: USD
5.61
+0.05 (0.90%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
5.60
-0.01 (-0.15%)
Bozordan keyin: Jun 26, 2026, 6:02 PM EDT
Abeona Therapeutics Inc., tijorat bosqichidagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda hayot uchun xavfli kasalliklarga gen va hujayra terapiyasini ishlab chiqadi. U recessive distrofik epidermoliz bullosa bilan og'rigan bemorlarni davolash uchun avtolog, hujayra asosidagi gen terapiyasi bo'lgan ZEVASKYNni ishlab chiqadi. Kompaniya shuningdek, X-bog'liq retinoshizni davolash uchun ABO-503; Stargardt kasalligini davolash uchun ABO-504; va autosomal dominant optik atrofiyani davolash uchun ABO-505ni ishlab chiqadi. Bundan tashqari, AIM vektor platformasi dasturlari orqali AAV asosidagi gen terapiyasini ishlab chiqmoqda. Kompaniya ilgari PlasmaTech Biopharmaceuticals, Inc. nomi bilan tanilgan va 2015 yil iyun oyida Abeona Therapeutics Inc. nomini o'zgartirgan. Abeona Therapeutics Inc. 1974 yilda tashkil etilgan va shtab-kvartirasi Ogayo shtatining Klivlend shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Brendan M. O'Malley J.D., Ph.D. | Chief Legal Officer |
| Dr. James A. Gow M.B.A., M.D., M.S. | SVP, Head of Clinical Development & Medical Affairs |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | SVP, Chief Commercial Officer & Head of Business Development |
| Mr. Brian Kevany Ph.D. | Chief Technical & Scientific Officer |
| Mr. Carl Denny | Senior Vice President of Regulatory Affairs |
| Mr. Gregory Gin |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-26 | S-8 | forms-8.htm |
| 2026-06-12 | 8-K | form8-k.htm |
| 2026-06-10 | 8-K | form8-k.htm |
| 2026-06-04 | 8-K | form8-k.htm |
| 2026-05-13 | 8-K | form8-k.htm |
| 2026-05-13 | 10-Q | form10-q.htm |
| 2026-05-04 | DEFA14A | formdefa14a.htm |
| 2026-04-27 | DEF 14A | formdef14a.htm |
| 2026-04-27 | ARS | formars.pdf |
| 2026-04-17 | PRE 14A | formpre14a.htm |
| Vice President of Investor Relations & Corporate Communications |
| Mr. Jon Voss | VP & Head of Quality |
| Mr. Joseph Walter Vazzano CPA | Chief Financial Officer |
| Ms. Gianine Esposito | Senior VP & Chief People Officer |
| Ms. Megan Callan | Vice President & Head of Quality |